The pharma firm's CEO, Branded Markets (India & Emerging Markets) told reporters that due to the sudden spike of Covid-19 cases in Russia, the arrival of Sputnik V doses are getting delayed, and the company expects the situation to ease by August-end
This picture has been used for representational purpose
Drug maker Dr Reddy's Laboratories said on Tuesday that the locally-manufactured Covid-19 Sputnik V vaccine is expected to be available in the September-October period. "The local manufacturers of Sputnik V vaccine are currently in the process of technology absorption and scale up, and we expect that the vaccine will be available from September-October period," the pharma firm's CEO, Branded Markets (India & Emerging Markets), M.V. Ramana, said.
ADVERTISEMENT
He told reporters that due to the sudden spike of Covid-19 cases in Russia, the arrival of Sputnik V doses are getting delayed, and the company expects the situation to ease by August-end. Dr Reddy's soft-launched the vaccine on May 14 after receiving Emergency Use Authorisation (EUA) in April. So far, the vaccine has been launched in about 80 cities and towns across India and over 2.5 lakh people have been administered the jab.
Also read: Sputnik V soft launched in over 50 cities in India, says Dr Reddy's
It expects to ramp up vaccination from August onwards after receiving balance doses for the second jab. The Hyderabad-based drug maker, which has tied up with Russian Direct Investment Fund (RIDF) for Sputnik V in India, is in discussions for ramping up supplies. The RIDF has tied up with six Indian pharma companies to manufacture Sputnik V. Ramana said Dr Reddy's will sell the first 125 million people doses (250 million vials).
On single dose Sputnik Light, he said Dr Reddy's was in the process of receiving data on it. The company will be approaching the Subject Expert Committee (SEC) under the Drugs Controller General of India with the updated data. As per the recommendation of the SEC, Dr Reddy's will be leveraging Russia Phase-3 trials. It is also waiting for the clinical data from the ongoing clinical trials of Sputnik V in Russia for 12-18 age group to seek approval in India. The trials in Russia are expected to be completed by October.
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever
Subscribe today by clicking the link and stay updated with the latest news!" Click here!
